PHAT

4.79

8.86% 0.39

Handel nachbörslich: 4.85 0.06 +1.25%

Phathom Pharmaceuticals Inc (PHAT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$4.40

Offen:

$4.41

24-Stunden-Volumen:

1.59M

Relative Volume:

1.55

Marktkapitalisierung:

$333.56M

Einnahmen:

Nettoeinkommen (Verlust:

$-297.11M

KGV:

-0.9229

EPS:

-5.19

Netto-Cashflow:

$-216.95M

1W Leistung:

-14.16%

1M Leistung:

-11.13%

6M Leistung:

-74.39%

1J Leistung:

-42.01%

1-Tages-Spanne:

$4.325

$4.85

1-Wochen-Bereich:

$4.325

$6.98

52-Wochen-Spanne:

$4.325

$19.71

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Firmenname

Phathom Pharmaceuticals Inc

Sektor

Healthcare (1170)

Branche

Biotechnology (673)

Telefon

(877) 742-8466

Adresse

100 CAMPUS DRIVE,, FLORHAM PARK, NJ

Mitarbeiter

112

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

PHAT's Discussions on Twitter

Vergleichen Sie PHAT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PHAT Phathom Pharmaceuticals Inc	4.79	333.56M	0	-297.11M	-216.95M	-5.19
VRTX Vertex Pharmaceuticals Inc	488.34	125.40B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	718.16	78.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	580.43	35.27B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	238.74	30.91B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	245.71	26.37B	3.32B	-860.46M	-1.04B	-8.32

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-14	Eingeleitet	Cantor Fitzgerald	Overweight
2024-05-03	Eingeleitet	Stifel	Buy
2024-01-05	Bestätigt	Needham	Buy
2023-08-09	Eingeleitet	H.C. Wainwright	Buy
2023-05-11	Hochstufung	Evercore ISI	In-line → Outperform
2023-03-13	Eingeleitet	Craig Hallum	Buy
2022-10-21	Eingeleitet	Jefferies	Buy
2022-05-06	Herabstufung	Evercore ISI	Outperform → In-line
2021-05-12	Hochstufung	Goldman	Sell → Neutral
2021-02-17	Eingeleitet	BMO Capital Markets	Outperform
2021-02-02	Eingeleitet	Guggenheim	Buy
2020-06-26	Herabstufung	Goldman	Neutral → Sell
2019-11-20	Eingeleitet	Evercore ISI	Outperform
2019-11-19	Eingeleitet	Goldman	Neutral
2019-11-19	Eingeleitet	Jefferies	Buy
2019-11-19	Eingeleitet	Needham	Buy

Alle ansehen

Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten

12:17 PM

Insider Buying: Asit Parikh Acquires 10,000 Shares of Phathom Ph - GuruFocus.com

12:17 PM

10:36 AM

Phathom Pharmaceuticals stock hits 52-week low at $4.34 - Investing.com India

10:36 AM

10:20 AM

Phathom Pharmaceuticals stock hits 52-week low at $4.34 By Investing.com - Investing.com UK

10:20 AM

06:43 AM

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Simply Wall St

06:43 AM

02:43 AM

Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $12.00 at The Goldman Sachs Group - Defense World

02:43 AM

Mar 10, 2025

Phathom Pharmaceuticals’ Earnings Call: Growth and Challenges - TipRanks

Mar 10, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 10, 2025

Mar 09, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Position Boosted by Rhumbline Advisers - Defense World

Mar 09, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from HC Wainwright - Defense World

Mar 09, 2025

Mar 08, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Needham & Company LLC - Defense World

Mar 08, 2025

Mar 07, 2025

Phathom Pharmaceuticals price target lowered to $12 from $18 at Goldman Sachs - TipRanks

Mar 07, 2025

H.C. Wainwright maintains $28 target on Phathom Pharma stock By Investing.com - Investing.com Canada

Mar 07, 2025

H.C. Wainwright maintains $28 target on Phathom Pharma stock - Investing.com

Mar 07, 2025